Here, we observed that, similar to the larger cohort, the only significant association was a reduced risk of multiple myeloma in individuals using GLP-1 receptor agonists (HR 0.33, 95% CI 0.12–0.90, p = 0.03). Here, GLP1R is linked to plasma cell myeloma.